Pfizer's Inspra helps heart-attack patients in trial; Brazil's Hypermarcas admits slow sales so far;

 @FiercePharma: That Novartis probe is responding to criminal complaints about lack of disclosure, per BloombergMore | Follow @FiercePharma

 @EricPFierce: Baxter Intl. investing more into international manufacturing, this time in Puerto Rico but it means 400 fewer jobs. Article | Follow @EricPFierce

> Brazil's Hypermarcas has started 2013 with weaker-than-expected sales but still expects to meet its target for operating profits this year, its CEO said. Report

> Pfizer's ($PFE) Inspra may help improve outcomes in patients who have experienced a particular type of heart attack known as STEMI, a study found. Report

> European regulators say new labeling requirements for drugs deemed risky should take effect in September as originally planned. Report

> Protection against whooping cough weakens a few years after small children receive their final booster vaccination against it. Report

Medical Device News

 @FierceMedDev: Stryker slapped with FDA warning letter. More | Follow @FierceMedDev

 @MarkHFierce: St. Jude Medical is releasing a next-gen stent imaging system in Japan, hoping to propel major interest. Article | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics IPO target keeps falling, from $41.9M to $29.3M to $20.1M and, now, just $14.3M. Report | Follow @DamianFierce

> Decision Diagnostics challenges J&J with diabetes test. Story

> Early-stage Alzheimer's blood test on U.K. team's agenda. More

> Crescendo rolls out iPhone app for RA Dx. Item

Biotech News

 @FierceBiotech: In case you missed it: Medtronic, Edwards headline this year's ACC news. Roundup | Follow @FierceBiotech

 @JohnCFierce: Another high flying cancer drug developer looks like a takeover. Puma turns Pfizer castoff into gold. Report | Follow @JohnCFierce

 @RyanMFierce: Shire has acquired Premacure AB for drug against rare eye disease. Release | Follow @RyanMFierce

> Analysts cheer decision to continue Merck's controversial Vytorin study. Article

> Puma Biotech shares roaring up amid M&A meow. Story

> Astellas dumps $390M pact with Ambit on eve of IPO. News

> Omthera files $75M IPO as it blueprints omega-3 drug launch. More

Pharma Manufacturing News

> Marken pushes international expansion with warehouse in China. Item

> Pfizer, Glaxo, others give Interpol money to fight counterfeiters. Report

> Catalent deals target China from 2 directions. Story

Biotech Research News

 @EmilyMFierce: The origin of ovarian cancer has evaded scientists, but researchers at Cornell may have found a possible source. More | Follow @EmilyMFierce

> New therapy shows promise in treating inflammatory breast cancer. Report

> Deleting a gene in mice prevents obesity. Article

> Salt may be risk factor for MS, other autoimmune diseases. Story

> Buildup of unwanted proteins may lead to dementia. Item

And Finally... Some experts defend niacin treatment for heart disease despite the results of a new study. Report

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.